Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) CEO Lynn Seely sold 438 shares of the business's stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $23.12, for a total value of $10,126.56. Following the sale, the chief executive officer directly owned 81,721 shares in the company, valued at $1,889,389.52. This trade represents a 0.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Lyell Immunopharma Price Performance
NASDAQ LYEL opened at $24.34 on Thursday. Lyell Immunopharma, Inc. has a 1-year low of $7.65 and a 1-year high of $45.00. The company has a market capitalization of $516.98 million, a P/E ratio of -1.06 and a beta of -0.14. The business has a 50 day moving average price of $27.98 and a 200 day moving average price of $19.60.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. On average, research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.
Analyst Ratings Changes
LYEL has been the topic of a number of research reports. HC Wainwright raised shares of Lyell Immunopharma from a "neutral" rating to a "buy" rating and increased their price objective for the company from $20.00 to $45.00 in a research note on Tuesday, December 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $45.00.
Check Out Our Latest Stock Report on LYEL
Hedge Funds Weigh In On Lyell Immunopharma
Several institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC grew its stake in Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock worth $94,000 after acquiring an additional 154,327 shares during the period. Acadian Asset Management LLC lifted its position in Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the period. Walleye Capital LLC acquired a new stake in Lyell Immunopharma in the 2nd quarter worth about $258,000. Marshall Wace LLP purchased a new stake in Lyell Immunopharma in the 2nd quarter valued at about $94,000. Finally, RBF Capital LLC acquired a new position in shares of Lyell Immunopharma during the 2nd quarter valued at about $884,000. Hedge funds and other institutional investors own 66.05% of the company's stock.
About Lyell Immunopharma
(
Get Free Report)
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
